secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0001651308-24-000039
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EC approves BeiGene's tislelizumab for three NSCLC indications in EU
--------------------------------------------------------------------

- EC approved tislelizumab on April 23, 2024 for first-line squamous NSCLC, first-line non-squamous PD-L1≥50%, and second-line after prior platinum therapy.
- Approval based on three Phase 3 RATIONALE trials (307, 304, 303) enrolling 1,499 patients, showing PFS and OS benefits.
- This is tislelizumab's second EU approval; previously approved for ESCC; brand will unify under TEVIMBRA later in 2024.
- BeiGene plans to launch in first EU countries in 2024; over 900,000 patients prescribed tislelizumab globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000039/0001651308-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000039/bgne-20240423.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer